Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 130.11
ARWR's Cash to Debt is ranked higher than
54% of the 895 Companies
in the Global Biotechnology industry.

( Industry Median: 27.79 vs. ARWR: 130.11 )
Ranked among companies with meaningful Cash to Debt only.
ARWR' s Cash to Debt Range Over the Past 10 Years
Min: 0  Med: 13.41 Max: No Debt
Current: 130.11
Equity to Asset 0.83
ARWR's Equity to Asset is ranked higher than
70% of the 670 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. ARWR: 0.83 )
Ranked among companies with meaningful Equity to Asset only.
ARWR' s Equity to Asset Range Over the Past 10 Years
Min: -32.54  Med: 0.71 Max: 0.91
Current: 0.83
-32.54
0.91
F-Score: 3
Z-Score: 0.77
M-Score: -2.54
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -25057.96
ARWR's Operating margin (%) is ranked lower than
96% of the 697 Companies
in the Global Biotechnology industry.

( Industry Median: -70.14 vs. ARWR: -25057.96 )
Ranked among companies with meaningful Operating margin (%) only.
ARWR' s Operating margin (%) Range Over the Past 10 Years
Min: -30443.43  Med: -3442.52 Max: -520.49
Current: -25057.96
-30443.43
-520.49
Net-margin (%) -24004.70
ARWR's Net-margin (%) is ranked lower than
96% of the 697 Companies
in the Global Biotechnology industry.

( Industry Median: -66.97 vs. ARWR: -24004.70 )
Ranked among companies with meaningful Net-margin (%) only.
ARWR' s Net-margin (%) Range Over the Past 10 Years
Min: -33502.86  Med: -3192.77 Max: -513.78
Current: -24004.7
-33502.86
-513.78
ROE (%) -65.76
ARWR's ROE (%) is ranked lower than
70% of the 807 Companies
in the Global Biotechnology industry.

( Industry Median: -31.22 vs. ARWR: -65.76 )
Ranked among companies with meaningful ROE (%) only.
ARWR' s ROE (%) Range Over the Past 10 Years
Min: -225.02  Med: -94.07 Max: -28.66
Current: -65.76
-225.02
-28.66
ROA (%) -58.57
ARWR's ROA (%) is ranked lower than
74% of the 902 Companies
in the Global Biotechnology industry.

( Industry Median: -27.13 vs. ARWR: -58.57 )
Ranked among companies with meaningful ROA (%) only.
ARWR' s ROA (%) Range Over the Past 10 Years
Min: -154.73  Med: -76.38 Max: -22.16
Current: -58.57
-154.73
-22.16
ROC (Joel Greenblatt) (%) -2311.46
ARWR's ROC (Joel Greenblatt) (%) is ranked lower than
72% of the 860 Companies
in the Global Biotechnology industry.

( Industry Median: -378.42 vs. ARWR: -2311.46 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ARWR' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -11843.37  Med: -1977.04 Max: -584.83
Current: -2311.46
-11843.37
-584.83
EBITDA Growth (3Y)(%) -2.20
ARWR's EBITDA Growth (3Y)(%) is ranked higher than
50% of the 454 Companies
in the Global Biotechnology industry.

( Industry Median: -2.40 vs. ARWR: -2.20 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ARWR' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -56.3  Med: -18.70 Max: 190.5
Current: -2.2
-56.3
190.5
EPS Growth (3Y)(%) -5.50
ARWR's EPS Growth (3Y)(%) is ranked lower than
51% of the 462 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. ARWR: -5.50 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ARWR' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -75.1  Med: -13.95 Max: 162.1
Current: -5.5
-75.1
162.1
» ARWR's 10-Y Financials

Financials (Next Earnings Date: 2016-02-09)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

ARWR Guru Trades in

Q2 2014

ARWR Guru Trades in Q2 2014

Steven Cohen 3,225,000 sh (+115.00%)
George Soros Sold Out
» More
Q2 2015

ARWR Guru Trades in Q2 2015

Steven Cohen 22,200 sh (New)
» More
Q3 2015

ARWR Guru Trades in Q3 2015

Paul Tudor Jones 17,447 sh (New)
Steven Cohen Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with ARWR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.91
ARWR's P/B is ranked higher than
66% of the 1125 Companies
in the Global Biotechnology industry.

( Industry Median: 2.66 vs. ARWR: 1.91 )
Ranked among companies with meaningful P/B only.
ARWR' s P/B Range Over the Past 10 Years
Min: 1.45  Med: 5.84 Max: 75.56
Current: 1.91
1.45
75.56
P/S 519.53
ARWR's P/S is ranked lower than
99.99% of the 1125 Companies
in the Global Biotechnology industry.

( Industry Median: 9.13 vs. ARWR: 519.53 )
Ranked among companies with meaningful P/S only.
ARWR' s P/S Range Over the Past 10 Years
Min: 0  Med: 152.10 Max: 2468
Current: 519.53
0
2468
Current Ratio 6.47
ARWR's Current Ratio is ranked higher than
60% of the 887 Companies
in the Global Biotechnology industry.

( Industry Median: 4.77 vs. ARWR: 6.47 )
Ranked among companies with meaningful Current Ratio only.
ARWR' s Current Ratio Range Over the Past 10 Years
Min: 0.01  Med: 2.83 Max: 22.28
Current: 6.47
0.01
22.28
Quick Ratio 6.47
ARWR's Quick Ratio is ranked higher than
61% of the 887 Companies
in the Global Biotechnology industry.

( Industry Median: 4.43 vs. ARWR: 6.47 )
Ranked among companies with meaningful Quick Ratio only.
ARWR' s Quick Ratio Range Over the Past 10 Years
Min: 0.01  Med: 3.57 Max: 22.28
Current: 6.47
0.01
22.28

Valuation & Return

vs
industry
vs
history
Price/Net Cash 2.68
ARWR's Price/Net Cash is ranked higher than
80% of the 747 Companies
in the Global Biotechnology industry.

( Industry Median: 6.00 vs. ARWR: 2.68 )
Ranked among companies with meaningful Price/Net Cash only.
ARWR' s Price/Net Cash Range Over the Past 10 Years
Min: 0.05  Med: 7.22 Max: 21.43
Current: 2.68
0.05
21.43
Price/Net Current Asset Value 2.54
ARWR's Price/Net Current Asset Value is ranked higher than
79% of the 899 Companies
in the Global Biotechnology industry.

( Industry Median: 7.24 vs. ARWR: 2.54 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ARWR' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 0.04  Med: 7.00 Max: 15.67
Current: 2.54
0.04
15.67
Price/Tangible Book 2.42
ARWR's Price/Tangible Book is ranked higher than
79% of the 1054 Companies
in the Global Biotechnology industry.

( Industry Median: 4.00 vs. ARWR: 2.42 )
Ranked among companies with meaningful Price/Tangible Book only.
ARWR' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.04  Med: 6.62 Max: 15.11
Current: 2.42
0.04
15.11
Earnings Yield (Greenblatt) (%) -89.45
ARWR's Earnings Yield (Greenblatt) (%) is ranked lower than
93% of the 859 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. ARWR: -89.45 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ARWR' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -101.29  Med: 0.00 Max: 0
Current: -89.45
-101.29
0

More Statistics

Revenue(Mil) $0
EPS $ -1.61
Beta2.37
Short Percentage of Float21.57%
52-Week Range $3.12 - 9.36
Shares Outstanding(Mil)59.55

Analyst Estimate

Sep16 Sep17
Revenue(Mil) 0 0
EPS($) -1.79 -1.79
EPS without NRI($) -1.79 -1.79

Latest Earnings Webcast

» More Conference Calls

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:HDP1.Germany,
Arrowhead Research Corp was originally incorporated in South Dakota in 1989, and was reincorporated in Delaware in 2000. It is a biopharmaceutical company developing targeted RNAi therapeutics. The Company is leveraging its proprietary drug delivery technologies to develop drugs based on the RNA interference mechanism that efficiently silences disease-causing genes. Its pipeline includes clinical programs in chronic hepatitis B virus and partner-based programs in obesity and oncology. The product include ARC-520, Adipotide, CRLX-101, Tubulin Inhibitor.The drug products are regulated by FDA under the Federal Food, Drug and Cosmetic Act (the "FDCA"), and other laws within the Public Health Service Act.
» More Articles for ARWR

Headlines

Articles On GuruFocus.com
Arrowhead Research Making Headway In The RNAi Therapy Platform Mar 09 2015 
Weekly CEO Buys Highlight: NRP, OPK, GAM, KEY, ARWR Oct 20 2014 
Arrowhead Research Corp. Reports Operating Results (10-Q) Feb 10 2011 
Weekly CFO Buys Highlight: JAZZ, VRTB, ASTM, ARWR, CGX Sep 04 2010 
Arrowhead Research Corp. Reports Operating Results (10-Q) May 13 2010 
Arrowhead Research Corp. Reports Operating Results (10-Q) Feb 11 2010 
Arrowhead Research Corp. Reports Operating Results (10-K) Dec 22 2009 
Arrowhead Research Corp. Reports Operating Results (10-Q) Aug 10 2009 
Arrowhead Research Corp. Reports Operating Results (10-Q) May 15 2009 
Arrowhead Research Corp. Reports Operating Results (10-Q) Feb 09 2009 

More From Other Websites
Arrowhead to Webcast Fiscal 2016 First Quarter Results Feb 02 2016
Arrowhead's ARC-AAT Granted EMA Orphan Drug Designation Jan 19 2016
Arrowhead’s ARC-AAT Granted EMA Orphan Drug Designation Jan 19 2016
ARROWHEAD RESEARCH CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of... Jan 14 2016
Healthcare Sector Equities under Review -- Amarin, Arrowhead Research, Zogenix, and PetMed Express Jan 13 2016
Arrowhead Research Corp. breached its 50 day moving average in a Bearish Manner : January 7, 2016 Jan 07 2016
Arrowhead Begins Dosing the Phase 2b MONARCH Combination Study of ARC-520 in Patients with Chronic... Jan 07 2016
Technical Coverage on Biotechnology Stocks - Agenus, Progenics Pharma, Arrowhead Research, and... Dec 28 2015
5 Stocks Ready for Breakouts Dec 18 2015
Pre-market Equity Watch on Biotechnology -- Agenus, Arrowhead Research, Spectrum Pharma, and... Dec 18 2015
ARROWHEAD RESEARCH CORP Financials Dec 17 2015
Edited Transcript of ARWR earnings conference call or presentation 14-Dec-15 9:30pm GMT Dec 15 2015
Arrowhead Research reports 4Q loss Dec 14 2015
Arrowhead Research reports 4Q loss Dec 14 2015
Arrowhead Research Corp Earnings Call scheduled for 4:30 pm ET today Dec 14 2015
Arrowhead Reports Fiscal 2015 Year End Results Dec 14 2015
Arrowhead Reports Fiscal 2015 Year End Results Dec 14 2015
ARROWHEAD RESEARCH CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Dec 14 2015
ARROWHEAD RESEARCH CORP Files SEC form 10-K, Annual Report Dec 14 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK